Sacklers, Purdue to pay $7.4 bn over opioid crisis: NY state

Sacklers, Purdue to pay $7.4 bn over opioid crisis: NY state

Purdue Pharma's OxyContin, one of the main prescription opioids that stoked the US addiction and overdose epidemic beginning in the early 2000s
Purdue Pharma's OxyContin, one of the main prescription opioids that stoked the US addiction and overdose epidemic beginning in the early 2000s. Photo: Handout / US Drug Enforcement Administration/AFP
Source: AFP

Several US states have reached a $7.4 billion settlement with the Sackler family and their pharmaceutical company Purdue over the opioid crisis that has ravaged the lives of millions of Americans, officials said Thursday.

The opioid addiction epidemic has caused more than 500,000 overdose deaths in the United States over two decades.

Thursday's settlement, which will see funds routed to communities and individuals affected by opioid, is the largest of several targeting the makers and sellers of the highly addictive drugs.

The $7.4 billion settlement was agreed "in principle with members of the Sackler family and their company Purdue Pharma for their instrumental role in creating the opioid crisis," New York Attorney General Letitia James's office said in a statement.

Purdue and other opioid makers and distributors were accused of encouraging free-wheeling prescription of their products through aggressive marketing tactics while hiding how addictive the drugs are.

Facing an avalanche of litigation, in 2021 Purdue pled guilty to three criminal charges over its marketing of OxyContin.

Read also

American Airlines shares fall on lackluster 2025 profit outlook

The Sacklers have consistently denied wrongdoing over the opioid crisis.

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.